69-05-6
基本信息
疟涤平
疟疾平
奎克林
奎納克林
盐酸米帕林
盐酸阿的平
喹吖因二盐酸
二盐酸喹吖因
二盐酸喹丫因
sn390
mecryl
866r.p.
palusan
ATABRINE
italchin
metochin
metoquin
palacrin
物理化学性质
熔点 | 249-251℃ (Decomposition) |
密度 | 1.2962 (rough estimate) |
折射率 | 1.6300 (estimate) |
储存条件 | +15C to +30C |
酸度系数(pKa) | pKa -6.3(H2O t undefined I not reported but low) (Uncertain) |
形态 | 黄色固体 |
PH值 | 3.0~5.0 (20g/l, 25℃) |
Merck | 14,8044 |
BRN | 4834013 |
稳定性 | 稳定的。与强氧化剂不相容。 |
EPA化学物质信息 | Quinacrine hydrochloride (69-05-6) |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H302 |
防范说明 | P264-P270-P301+P312-P501 |
危险品标志 | Xn |
危险类别码 | 22-36/37/38 |
安全说明 | 36/37/39 |
WGK Germany | 3 |
RTECS号 | AR7875000 |
毒性 | LD50 oral in rabbit: 433mg/kg |
图谱信息
疟疾平(69-05-6)质谱(MS)疟疾平(69-05-6)核磁图(1HNMR)疟疾平(69-05-6)核磁图(13CNMR)疟疾平(69-05-6)红外图谱(IR1)疟疾平(69-05-6)红外图谱(IR2)常见问题列表
Target | Value |
PLA2
() |
Quinacrine (5-20 μM; 24 hours) inhibits the growth of SGC-7901 cells.
Quinacrine (7.5 and 15 μM; 24 hours) induces apoptosis in SGC-7901 cells, which is associated with mitochondria-dependent signal pathway and involves p53 upregulation and caspase-3 activation pathway.
Quinacrine (15 μM; 24 hours) treatment significantly increased the levels of proapoptotic proteins, including cytochrome c, Bax, and p53, and decreased the levels of antiapoptotic protein Bcl-2, thus shifting the ratio of Bax/Bcl-2 in favor of apoptosis .
Cell Viability Assay
Cell Line: | SGC-7901 cells |
Concentration: | 0, 5, 10, 15, and 20 μM |
Incubation Time: | 24 hours |
Result: | Cell viability was inhibited in a dose-dependent manner, and the mean IC 50 value is 16.18 μM. |
Apoptosis Analysis
Cell Line: | SGC-7901 cells |
Concentration: | 7.5 and 15 μM |
Incubation Time: | 24 hours |
Result: | The percentage of apoptotic cells, including the early phase and late phase apoptosis, increased to 26.30%, compared with control group of 3.37%. |
Western Blot Analysis
Cell Line: | SGC-7901 cells |
Concentration: | 15 μM |
Incubation Time: | 24 hours |
Result: |
The relative quantity of cytochrome c protein was upregulated, increased from 0.10 to 0.24.
The relative quantity of p53 protein was dramatically increased, from 0.06 to 0.19. The Bax/Bcl-2 ratio was dramatically elevated from 1.21 to 2.59. |
Quinacrine (100 mg/kg three times per week for two consecutive weeks) significantly suppresses circulating blast cells at days 30/31 and increases the median survival time (MST). Quinacrine does not decrease the body weight of treated animals at the tested dose.
Animal Model: | Female SCID mice with acute myeloid leukemia (AML)-PS model |
Dosage: | 100 mg/kg |
Administration: | Administered by oral gavage (po); three times a week for two consecutive weeks |
Result: |
In the first AML mouse in vivo study, evaluation of circulating leukemic cells detected in blood samples (in percent of white blood cells (WBC)) at day 30/31 showed 72% human tumor cells in the control mice, whereas in mice treated with Quinacrine, this was only 2.2%.
The MST of control mice was 34 days whereas it was 46 days in Quinacrine-treated mice. |